Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1

As the most malignant breast cancer subtype, triple-negative breast cancer (TNBC) does not have effective targeted therapies clinically to date. As a selective Sp1 inhibitor, Mithramycin A (MIT) has been reported to have anti-tumor activities in multiple cancers. However, the efficacy and the mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rong, Zhi, Xu, Zhou, Zhongmei, Zhang, Hailin, Yang, Runxiang, Zou, Tianning, Chen, Ceshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773554/
https://www.ncbi.nlm.nih.gov/pubmed/29348684
http://dx.doi.org/10.1038/s41598-018-19489-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773554/
https://www.ncbi.nlm.nih.gov/pubmed/29348684
http://dx.doi.org/10.1038/s41598-018-19489-6

Ejemplares similares